OncoVax-P liposomal vaccine based on recombinant prostate specific antigen data

Jenner announced results from four Phase I/II studies, showing good tolerability, and clinical benefit in half of the patients. An immune response was

Read the full 238 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE